WASHINGTON, March 24 /PRNewswire-FirstCall/ -- New data presented today at the National Hispanic Medical Association (NHMA) annual meeting showed that AstraZeneca's CRESTOR(R) (rosuvastatin calcium) at 10 and 20 mg reduced LDL-C or "bad" cholesterol by 45.2 and 50.0 percent, compared to 35.9 and 42.4 percent with atorvastatin at milligram-equivalent doses in Hispanic patients with elevated cholesterol (p